Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hypertension treatment Tracleer is now available upon prescription to all patients in Japan. The availability follows formal approval by the Japanese Ministry of Health, Labor and Welfare for the use of Tracleer to treat all forms of pulmonary arterial hypertension last April.
Subscribe to our email newsletter
In early June, the same authority granted full reimbursement status for this orally available dual endothelin receptor antagonist. Tracleer(r) is being made available in Japan through Actelion’s own affiliate, with initially 35 territory managers focusing on hospital-based physicians.
Dr Jean-Paul Clozel CEO of Actelion, said: “With today’s launch in Japan, Actelion has realized its strategic goal of commercializing Tracleer(r) with its own infrastructure in all key pharmaceutical markets worldwide.
“We can now further leverage our worldwide capabilities in clinical development, regulatory affairs and marketing and sales with new innovative compounds from our own drug discovery efforts or, should the opportunity arise, from in-licensed or acquired drugs.”